German government gives health research a big leg up


Berlin – In the second major biotech-related funding project from the German Federal Ministry of Education and Research (BMBF) within two months, the ministry announced that Germany will be spending more than EUR5.5bn on a programme for health research by 2014. In December of last year, Research Minister Annette Schavan started a EUR2.4bn funding scheme for the bio-economy. The lion’s share from the most recent health research programme that is to be funded by the BMBF will be invested in six German Centers for Health Research. The aim is to help top scientists and researchers from both university medicine and non-academic facilities work together, and provide them with long term funding. “We are pursuing the strategy to bring together the best scientists and thereby promote the rapid transfer of knowledge from the laboratory into practice,” said Schavan. The German Centre for Neurodegenerative Diseases (DZNE) and the German Center for Diabetes Research have already begun work. The four other centres – for Infection, Lung Diseases, Cardiovascular Diseases and Cancer – were announced in December, and will begin work soon.

Germany, FranceGermany


Martinsried/Paris - Sanofi has done some Christmas shopping in Munich and has licensed Scil Technology’s programme for the regenerative treatment of osteoarthritis and cartilage disorders. Under the agreement, Scil could reap up...



Monheim - It's nearly Christmas, and Bayer Crop Science gives out some presents. As the company announced, a $750 million settlement with U.S. rice farmers is now binding and can move forward. In summer the German firm had agreed...



Bonn – Germany’s federal government is prolonging one of its most successful measures to date for stimulating the establishment of high-tech companies – the High-Tech-Gründerfonds (HTGF). The HTGF was launched in 2005 with €272m...



Leverkusen – One short statement from the European Medicines Agency (EMA) means one giant step for German biotech company Biofrontera. The agency issued a favourable opinion on the firm’s marketing approval application for its...



While the European sovereign debt crisis keeps capital markets in a choke-hold, with potential negative effects on the financing situation in many industries – including biotech – there was encouraging news for drug-developing...



Heidelberg – There is still life in the European life science finance. EMBL Ventures has closed a €40m fund. The early stage investor and the venture capital arm of the European Molecular Biology Laboratory(EMBL) announced the...



Düsseldorf – BIO-Europe 2011 in Düsseldorf has again broken all previous records in terms of participants and company numbers. More than 3,000 representatives from 1,800 companies registered for Europe‘s largest partnering event....



Brussels/San Francisco – As the biggest biotech partnering event on the continent, BioEurope, draws to a close, the venture capital community sent ambivalent messages for life sciences. Dow Jones VentureSource, an analyst,...

Displaying results 11 to 20 out of 454

< Previous 11-20 Next >

© 2007-2015 BIOCOM


All Events


Product of the week


Current issue

All issues